drugset / Trial / NCT07230652
A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled, ascending multiple oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects and/or subjects with stable schizophrenia.
Timeline
- Start
- 2025-08-20
- Primary completion
- 2025-12-31
- Completion
- 2026-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY03020 | Unknown | — | Oral |